Follow us on Facebook  Follow us on Twitter  Investors Hub Board
Wall Street Newscast  Where Wall Street Listens

Join Our Email List
Email:  

Home | Email Alerts | Message Board | Twitter | Awareness Services | Contact
stock picks



PuraMed BioScience, Inc (OTC:PMBSD)
1326 Schofield Avenue
Schofield, WI 54476
Phone: 715-359-6373
Email: info@southstreetmedia.com 
Real-Time Quote

PMBS Mailing List

PMBS Message Board



About PuraMed BioScience, Inc.

PuraMed BioScience engages in the research, development, and marketing of non-prescription medicinal and healthcare products. In addition to LipiGesic M, PuraMed BioScience plans to launch LipiGesic H for tension-type headaches as well as LipiGesic PM, which provides a remedy for insomnia and other sleep disorders. For more information visit www.puramedbioscience.com


Shares Authorized:  Public Float: UR
Shares Outstanding: 40 million Price Target: $0.05+

*
based on OTC Markets data


PMBSD Nears Development of Cannabis Medication for Treatment of Epilepsy
Last Updated:
Oct. 10, 2014 - 11:00am EST

(NEW YORK)--PuraMed BioScience, Inc. (OTC:PMBSD), and developer of over-the-counter health and wellness products, announced it is nearing completion of a CBD cannabis rich medication for the treatment of epilepsy.

The Company is developing an over the counter medication, using cannabis hemp oil (CBD) for the treatment of Epilepsy. Recent studies have shown CBD to be extremely effective in the treatment of epilepsy, and with PBMSD already having a natural over the counter migraine product, MigraPure, the combination of both could yield a medication with wide ranging benefits to suffers of epilepsy, and chronic migraines.

PMBSD already has distribution relationships with such large big box chains, such as Walgreens, and CVS, so developing a product from production to store shelves could be much easier compared to new over the counter developers.

As of Oct. 7, 2014, the Company has around 40 million common shares issued and outstanding, given PMBSD a market cap of around $200,000 to $400,000.




Safe Harbor Statements:

This investor presentation may include statements that may constitute forward-looking statements made pursuant to the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Although the Company believes that the expectations reflected in such forward-looking statements are based on reasonable assumptions, such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected.

Disclaimer
:

This is NOT a solicitation to Buy or Sell any security, but rather is for informational purposes only. Content contained herein includes facts, views, opinions and recommendations of individuals and organizations deemed of interest. Wall Street Newscast ("WSNC") does not guarantee the accuracy, completeness or timeliness of, or otherwise endorse these views, opinions or recommendations, or give investment advice. WSNC, its affiliates, or directors, may or may not hold a position in the above security from time to time, and investors are encourage to consider this as a possible conflict of interest when reviewing this information. In Compliance with SEC Rule 17B Wall Street Newscast was compensated one thousand dollars for research and media alert. WSNC may hold a position in above securities from time to time, and thus should be considered a possible conflict of interest when reviewing this report and information. These investments may involve a high degree of risk, thus investors are highly encouraged to consult with a financial advisor before any and all investments.

Your use of this website is subject to our terms & conditions. Wall Street Newscast 1998 - 2011

This website includes statements that may constitute forward-looking statements made pursuant to the safe harbor
provisions of the U.S. Private Securities Litigation Reform Act of 1995. Although the Company believes that the
expectations reflected in such forward-looking statements are based on reasonable assumptions, such statements
are subject to risks and uncertainties that could cause actual results to differ materially from those projected.